Literature DB >> 21881006

Interictal encephalography can influence patient selection for methylprednisolone therapy in pediatric refractory epilepsy.

Eli Heyman1, Eli Lahat, Revital Gandelman-Marton.   

Abstract

We describe our experience with intravenous methylprednisolone pulse therapy in older children with refractory epilepsy. Patients with refractory epilepsy, who were treated with steroids between 2005 and 2010, were retrospectively selected from the database of the pediatric epilepsy clinic at Assaf Harofeh Medical Center. Eight patients (5 boys) aged 1.1 to 9 years (5.2 ± 2.6) were identified. Intravenous methylprednisolone 30 mg/kg/d was given to all patients for 5 days in addition to a stable dosage of the regular antiepileptic drugs. Transient side effects were reported in 4 of the patients during pulse therapy. Significant clinical improvement was noted in 4 patients, accompanied by a significant reduction of the amplitude of the spike-slow wave discharges on the electroencephalogram (EEG). Children with refractory epilepsy, abnormal EEG background, and high-amplitude spike-slow wave discharges appear to be the best candidates for intravenous methylprednisolone pulse therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21881006     DOI: 10.1177/0883073811414905

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  2 in total

1.  Intravenous methylprednisolone pulse therapy for children with epileptic encephalopathy.

Authors:  Maria Carmela Pera; Giovanna Randazzo; Silvia Masnada; Serena Donetti Dontin; Valentina De Giorgis; Umberto Balottin; Pierangelo Veggiotti
Journal:  Funct Neurol       Date:  2015 Jul-Sep

2.  Intravenous Methylprednisolone Versus Oral Prednisolone for West Syndrome: A Randomized Open-Label Trial.

Authors:  Dipti Kapoor; Suvasini Sharma; Divyani Garg; Sukla Samaddar; Isha Panda; Bijoy Patra; Sharmila B Mukherjee; Harish K Pemde
Journal:  Indian J Pediatr       Date:  2021-02-11       Impact factor: 1.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.